Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma
Alessandro Vitale,Pierluigi Romano,Umberto Cillo,Writing Group for the HE.RC.O.LE.S Collaborative Group,Writing Group for the ITA.LI.CA Collaborative Group,HE.RC.O.LE.S and ITA.LI.CA Collaborative Groups,Andrea Lauterio,Angelo Sangiovanni,Giuseppe Cabibbo,Gabriele Missale,Mariarosaria Marseglia,Franco Trevisani,Francesco Giuseppe Foschi,Federica Cipriani,Simone Famularo,Fabio Marra,Carlo Saitta,Matteo Serenari,Gianpaolo Vidili,Filomena Morisco,Eugenio Caturelli,Andrea Mega,Filippo Pelizzaro,Daniele Nicolini,Francesco Ardito,Mattia Garancini,Alberto Masotto,Gianluca Svegliati Baroni,Francesco Azzaroli,Edoardo Giannini,Pasquale Perri,Andrea Scarinci,Andrea Pierluigi Fontana,Maurizia Rossana Brunetto,Maurizio Iaria,Maria Di Marco,Gerardo Nardone,Tommaso Dominioni,Quirino Lai,Cecilia Ferrari,Gian Ludovico Rapaccini,Sacco Rodolfo,Maurizio Romano,Simone Conci,Marco Zoli,Maria Conticchio,Matteo Zanello,Giuseppe Zimmitti,Luca Fumagalli,Albert Troci,Paola Germani,Antonio Gasbarrini,Giuliano La Barba,Michela De Angelis,Stefan Patauner,Sarah Molfino,Mauro Zago,Enrico Pinotti,Anna Chiara Frigo,Gian Luca Baiocchi,Antonio Frena,Luigi Boccia,Giorgio Ercolani,Paola Tarchi,Michele Crespi,Marco Chiarelli,Moh'd Abu Hilal,Matteo Cescon,Riccardo Memeo,Andrea Ruzzenente,Giacomo Zanus,Guido Griseri,Massimo Rossi,Marcello Maestri,Raffaele Della Valle,Alessandro Ferrero,Gian Luca Grazi,Fabrizio Romano,Felice Giuliante,Marco Vivarelli,Elio Jovine,Guido Torzilli,Luca Aldrighetti,Luciano De Carlis,Marco Busti,Giulia Nezi,Riccardo De Carlis,Francesca Ratti,Flavio Milana,Matteo Donadon,Laura Marinelli,Francesco Razionale,Francesca Carissimi,Mauro Alessandro Scotti,Cristina Ciuli,Valerio De Peppo,Nadia Russolillo,Mauro Giuffrida,Francesca De Stefano,Jacopo Peverada,Zoe Larghi Laureiro,Angelo Franceschi,Patrizia Pelizzo,Ivan Marchitelli,Annachiara Casella,Alberto Manzoni,Alessia Malagnino,Pietro Calcagno,Francesco Cammarata,Luca Pennacchi,Davide Cosola,Pio Corleone,Alessandro Cucchetti,Guido Mantovani,Francesca Notte,Mauro Montuori,Gloria Allegrini,Calogero Cammà,Ciro Celsa,Paolo Giuffrida,Carmelo Marco Giacchetto,Gabriele Rancatore,Maria Vittoria Grassin,Roberta Ciccia,Alessandro Grova,Mauro Salvato,Elisabetta Biasini,Andrea Olivani,Rusi Chen,Alessandro Granito,Fabio Piscaglia,Bernardo Stefanini,Francesco Tovoli,Maurizio Biselli,Laura Bucci,Lorenzo Lani,Benedetta Stefanini,Vittoria Bevilacqua,Dante Berardinelli,Alberto Borghi,Andrea Casadei Gardini,Fabio Conti,Anna Chiara Dall'Aglio,Giorgio Ercolan,Claudia Campani,Chiara Di Bonaventura,Stefano Gitto,Maria Stella Franzè,Assunta Sauchella,Pietro Coccoli,Antonio Malerba,Mario Capasso,Maria Guarino,Valentina Lauria,Giorgia Ghittoni,Giorgio Pelecca,Anna Sartori,Angela Imondi,Barbara Penzo,Alessandro Inno,Fabiana Marchetti,Alessandro Di Bucchianico,Elton Dajti,Federico Ravaioli,Maria Corina Plaz Torres,Giulia Pieri,Filippo Olivieri,Veronica Romagnoli,Nicoletta de Matthaeis,Ester Marina Cela,Antonio Facciorusso,Francesca Romana Ponziani
DOI: https://doi.org/10.1001/jamasurg.2024.1184
2024-08-01
Abstract:Importance: The 2022 Barcelona Clinic Liver Cancer algorithm currently discourages liver resection (LR) for patients with multinodular hepatocellular carcinoma (HCC) presenting with 2 or 3 nodules that are each 3 cm or smaller. Objective: To compare the efficacy of liver resection (LR), percutaneous radiofrequency ablation (PRFA), and transarterial chemoembolization (TACE) in patients with multinodular HCC. Design, setting, and participants: This cohort study is a retrospective analysis conducted using data from the HE.RC.O.LE.S register (n = 5331) for LR patients and the ITA.LI.CA database (n = 7056) for PRFA and TACE patients. A matching-adjusted indirect comparison (MAIC) method was applied to balance data and potential confounding factors between the 3 groups. Included were patients from multiple centers from 2008 to 2020; data were analyzed from January to December 2023. Interventions: LR, PRFA, or TACE. Main outcomes and measures: Survival rates at 1, 3, and 5 years were calculated. Cox MAIC-weighted multivariable analysis and competing risk analysis were used to assess outcomes. Results: A total of 720 patients with early multinodular HCC were included, 543 males (75.4%), 177 females (24.6%), and 350 individuals older than 70 years (48.6%). There were 296 patients in the LR group, 240 who underwent PRFA, and 184 who underwent TACE. After MAIC, LR exhibited 1-, 3-, and 5-year survival rates of 89.11%, 70.98%, and 56.44%, respectively. PRFA showed rates of 94.01%, 65.20%, and 39.93%, while TACE displayed rates of 90.88%, 48.95%, and 29.24%. Multivariable Cox survival analysis in the weighted population showed a survival benefit over alternative treatments (PRFA vs LR: hazard ratio [HR], 1.41; 95% CI, 1.07-1.86; P = .01; TACE vs LR: HR, 1.86; 95% CI, 1.29-2.68; P = .001). Competing risk analysis confirmed a lower risk of cancer-related death in LR compared with PRFA and TACE. Conclusions and relevance: For patients with early multinodular HCC who are ineligible for transplant, LR should be prioritized as the primary therapeutic option, followed by PRFA and TACE when LR is not feasible. These findings provide valuable insights for clinical decision-making in this patient population.